Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.37 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.37 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.40 |
| ▸ | PPARA | Q07869 | 8/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2867978 | 1.00 | ACLY (0.50) | ACLYACACBACACATBXAS1PPARA | |
| SCHEMBL232205 | 0.98 | ACLY (0.52) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL621977 | 0.93 | ACLY (0.53) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL562371 | 0.93 | ACLY (0.53) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL561963 | 0.91 | ACLY (0.57) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL1175992 | 0.91 | ACLY (0.57) | ACLYACACBACACATBXAS1PPARA | |
| SCHEMBL154712 | 0.91 | ACLY (0.55) | ACLYACACBACACATBXAS1PPARA | |
| SCHEMBL250911 | 0.89 | ACLY (0.59) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL561987 | 0.86 | KDM4E (0.35) | ACLYACACBACACACYP1A2CYP2C9 | |
| SCHEMBL1106837 | 0.86 | ACLY (0.43) | ACLYACACBACACATBXAS1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583888-B2 | Bi-specific extracellular matrix binding peptides and methods of use thereof | UNIVERSITY OF TARTU (EE) | 2026-03-24 | — | — | US | disclosed |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260034236-A1 | NEW DRUG COMPLEX | KOWA COMPANY, LTD. (JP) | 2026-02-05 | — | — | US | disclosed |
| US-20250361270-A1 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4570272-A1 | NEW DRUG COMPLEX | KOWA COMPANY, LTD. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-12290569-B2 | Methods and compositions using peptides and proteins with c-terminal elements | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-05-06 | — | — | US | disclosed |
| US-12195558-B2 | Targeted delivery system and methods of use therefor | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-01-14 | — | — | US | disclosed |
| CN-114685611-B | Matrix metalloproteinase cleavable and serine proteinase cleavable substrates and methods of use thereof | 西托姆克斯治疗公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-114685661-B | Matrix metalloproteinase cleavable and serine proteinase cleavable substrates and methods of use thereof | 西托姆克斯治疗公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119119209-A | Matrix metalloproteinase cleavable and serine proteinase cleavable substrates and methods of use thereof | 西托姆克斯治疗公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2007076501-A2 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070122835-A1 | Methods for detection of genetic disorders | RAVGEN, INC. | 2007-05-31 | — | — | US | disclosed |
| EP-1484338-B1 | Methods and compositions for inhibiting neoplastic cell growth | GENENTECH INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060160105-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060121452-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| CN-1720336-A | Use of A33 antigens and JAM-IT | GENENTECH BIOTECH INC (US) | 2006-01-11 | — | — | CN | disclosed |
| CN-1607960-A | Glycoprotein compositions | GENENTECH INC (US) | 2005-04-20 | — | — | CN | disclosed |
| CN-1578673-A | Methods for identifying polypeptide antigens associated with diseases involving abnormal cell proliferation and compositions for treating such diseases | GENENTECH INC (US) | 2005-02-09 | — | — | CN | disclosed |
| CN-1549821-A | A system for antibody expression and assembly | — | 2004-11-24 | — | — | CN | disclosed |
| CN-1464908-A | Multivalent antibodies and uses thereof | GENENTECH INC (US) | 2003-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CMKLR2, CRKL, CMKLR1 | TTR 3125/4885CHRM1 3659/4885ADRA1A 4155/4885 |
| US-20260034236-A1 | NEW DRUG COMPLEX | OPRM1, ABCC1, OPRD1 | TTR 4242/4885CHRM1 143/4885ADRA1A 335/4885 |
| US-12583888-B2 | Bi-specific extracellular matrix binding peptides and methods of use thereof | FN1, EDNRB, TNFSF11 | TTR 517/4885CHRM1 3667/4885ADRA1A 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.